Pfizer ADC Adcetris gains additional lymphoma indication

by
Contributor since / Followers

4 weeks ago

The U.S. FDA has granted an additional approval for Pfizer’s (NYSE:PFE) antibody-drug conjugate Adcetris (brentuximab vedotin), this time for large B-cell lymphoma (LBCL).
The new indication is specifically as a third-line therapy for those ineligible for autologous hematopoietic stem cell

Tags: PFE